Johnson & Johnson : New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
Updated results from the MRD cohort of the Phase 2 CAPTIVATE study also highlight potential for treatment-free remissions with IMBRUVICA® plus venetoclax in an oral presentation at ASH... | December 11, 2021
Source: marketscreener.com